Market capitalization | $12.38b |
Enterprise Value | $25.15b |
P/E (TTM) P/E ratio | 21.63 |
EV/FCF (TTM) EV/FCF | 17.07 |
EV/Sales (TTM) EV/Sales | 1.20 |
P/S ratio (TTM) P/S ratio | 0.59 |
P/B ratio (TTM) P/B ratio | 0.83 |
Dividend yield | 3.05% |
Last dividend (FY24) | $0.64 |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
19 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:
19 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 5,131 5,131 |
2%
2%
|
|
Gross Profit | 1,256 1,256 |
4%
4%
|
|
EBITDA | 793 793 |
9%
9%
|
EBIT (Operating Income) EBIT | 380 380 |
11%
11%
|
Net Profit | 201 201 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Helen Giza |
Employees | 119,845 |
Founded | 1996 |
Website | www.freseniusmedicalcare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.